Journal
ANESTHESIA AND ANALGESIA
Volume 123, Issue 3, Pages 670-681Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1213/ANE.0000000000001461
Keywords
-
Categories
Funding
- NIH/NIGMS [R01GM103842-01]
- NIEHS Center for Environmental Health in Northern Manhattan
Ask authors/readers for more resources
Exposure to carbon monoxide (CO) during general anesthesia can result from volatile anesthetic degradation by carbon dioxide absorbents and rebreathing of endogenously produced CO. Although adherence to the Anesthesia Patient Safety Foundation guidelines reduces the risk of CO poisoning, patients may still experience subtoxic CO exposure during low-flow anesthesia. The consequences of such exposures are relatively unknown. In contrast to the widely recognized toxicity of high CO concentrations, the biologic activity of low concentration CO has recently been shown to be cytoprotective. As such, low-dose CO is being explored as a novel treatment for a variety of different diseases. Here, we review the concept of anesthesia-related CO exposure, identify the sources of production, detail the mechanisms of overt CO toxicity, highlight the cellular effects of low-dose CO, and discuss the potential therapeutic role for CO as part of routine anesthetic management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available